Recently Featured

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

May 20, 2026
Bristol Myers Squibb (BMS) and Hengrui Medicine have announced a significant $15.2 billion collaboration aimed at advancing early-stage drug development. This partnership will facilitate the exchange of rights to specific programs in both the Chinese and US markets, allowing both companies to leverage their strengths in innovative therapies. The collaboration centers on five promising assets,…

EMA Actively Monitoring Cruise Ship Hantavirus Outbreak

May 19, 2026
The European Medicines Agency (EMA) is actively monitoring an outbreak of hantavirus linked to a cruise ship, collaborating closely with other European Union bodies. This outbreak has been identified as involving the Andes hantavirus, a strain known for its potential health risks. The emergence of this virus in a cruise ship setting raises significant concerns…

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

May 19, 2026
Bristol Myers Squibb has entered a significant drugmaking alliance with China’s Hengrui Medicine, a deal valued at up to $15.2 billion. This collaboration encompasses the development of as many as 13 drugs, highlighting the increasing synergy between Chinese pharmaceutical companies and their counterparts in the U.S. and Europe. The partnership is indicative of a broader…

Eli Lilly Pauses Indian Obesity Awareness Campaign Following Regulatory Notices

May 19, 2026
Eli Lilly has halted its obesity awareness campaign in India due to a regulatory notice concerning compliance with advertising rules for prescription medications, as reported by Reuters. This decision underscores the increasing scrutiny that pharmaceutical companies face regarding their marketing practices in emerging markets. The Indian regulatory environment is evolving, and companies must navigate a…

Ongoing Cases